Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradermal incobotulinumtoxinA for facial seborrheic dermatitis
TCTR20260122009Phase 2Recruiting
- Sponsor
- Strategic Wisdom and Research Institute
- Start
- Jan 2026
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of botulinum toxin type A, ketoconazole in seborrheic dermatitis (SD), sponsored by Strategic Wisdom and Research Institute. Started Jan 2026; status: recruiting.
02
Drugs
botulinum toxin type Aketoconazole
03
Conditions
seborrheic dermatitis (SD)
Beyond the preview
Go deeper on TCTR20260122009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260122009.